Rheumatology International最新文献

{"title":"The journey of patients with musculoskeletal complaints in Europe: a cross-sectional European survey.","authors":"Magali Wagner, Teresa Otón, Felix Muehlensiepen, Karin Stratingh, Estíbaliz Loza, Rachel Knevel, Loreto Carmona","doi":"10.1007/s00296-025-05863-x","DOIUrl":"10.1007/s00296-025-05863-x","url":null,"abstract":"<p><p>Rheumatic and musculoskeletal diseases (RMDs) are highly prevalent and place a significant socioeconomic burden on healthcare systems. However, their diagnosis and management remain suboptimal. This study aimed to analyze healthcare-seeking behaviors, key touchpoints, access barriers, and diagnostic pathways for individuals experiencing initial or progressive symptoms of RMDs across European countries. Understanding these differences is crucial for improving early access to specialized care. A cross-sectional online survey was conducted with 141 participants from seven European countries, including 67 rheumatologists and 39 general practitioners (GPs). The survey assessed initial healthcare-seeking behaviors, delays in diagnosis, and perceived barriers to specialized rheumatology care. Descriptive and inferential statistical methods were used for data analysis. The survey indicated that individuals experiencing RMD symptoms primarily seek information through internet research and GP consultations. Despite their role as primary gatekeepers, GPs' knowledge of RMDs was generally perceived as moderate to low. Significant disparities in access to rheumatological diagnostics, time to diagnosis, and treatment, coupled with organizational barriers between primary and specialist care, were reported across most countries. Spanish participants reported the longest diagnostic delays, while Swedish respondents experienced the shortest. Additionally, access to sacroiliac MRI was limited in Hungary and Spain, whereas glucocorticoids were widely available across all countries according to the participants. The study also revealed that early arthritis clinics were most accessible in the UK from the participants' perspectives. Significant variations in healthcare access for patients with RMDs persist across Europe. Strategies to enhance early detection, including GP education and improved specialist accessibility, are essential to optimizing patient outcomes.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"107"},"PeriodicalIF":3.2,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methotrexate associates with ischemic cardiovascular risk reduction in males but not females: a transatlantic cardiovascular consortium for people with rheumatoid arthritis observational study.","authors":"George A Karpouzas, Sarah R Ormseth, Piet Van Riel, Elena Myasoedova, Miguel A Gonzalez-Gay, Alfonso Corrales, Solbritt Rantapaa-Dahlqvist, Petros Sfikakis, Patrick Dessein, Carol A Hitchon, Virginia Pascual-Ramos, Irazu Contreras Yanez, Iris Jazmín Colunga-Pedraza, Dionicio Angel Galarza-Delgado, Jose Azpiri-Lopez, Anne Grete Semb, Durga Prasanna Misra, George D Kitas, Ellen M Hauge","doi":"10.1007/s00296-025-05838-y","DOIUrl":"10.1007/s00296-025-05838-y","url":null,"abstract":"<p><strong>Objective: </strong>Patients with rheumatoid arthritis (RA) experience higher cardiovascular risk. Methotrexate may decrease this risk, although it is unclear whether males and females similarly benefit. We explored the influence of sex on the effect of methotrexate use on cardiovascular risk in RA.</p><p><strong>Methods: </strong>An observational cohort of 4362 patients, 3223 (73.9%) females, without cardiovascular disease were included from an international cardiovascular consortium for RA. Outcomes were (a) major adverse cardiovascular events (MACE) including cardiovascular death, myocardial infarction, or stroke and (b) any ischemic cardiovascular events (iCVE) including MACE, angina, revascularization, transient ischemic attack, and peripheral arterial disease. The effects of sex, prevalent methotrexate use at enrollment visit and their interaction on MACE and iCVE were assessed with multivariable Cox regression models, reporting adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>There were 237 first MACE and 358 first iCVE. The sex by methotrexate interaction was significant for MACE (p = 0.005) and iCVE (p = 0.006), suggesting the effect of methotrexate use on cardiovascular risk differed among males and females. In males, methotrexate use associated with lower risk of MACE (HR 0.32, [95% CI 0.12-0.83]) and iCVE (HR 0.43 [95% CI 0.21-0.85]). In females, methotrexate use was not associated with MACE (p = 0.267) or iCVE (p = 0.407). In sensitivity analyses, models with inverse probability of treatment weighting and models additionally adjusting for inflammation yielded similar results.</p><p><strong>Conclusion: </strong>Methotrexate use associated with cardiovascular benefit in males but not females with RA and the effect was independent of inflammation.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"106"},"PeriodicalIF":3.2,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-intensity resistance training in patients with myositis - 1-year follow-up on a randomised controlled trial.","authors":"Kasper Yde Jensen, Per Aagaard, Charlotte Suetta, Jakob Lindberg Nielsen, Rune Dueholm Bech, Henrik Daa Schrøder, Jan Christensen, Casper Simonsen, Louise Pyndt Diederichsen","doi":"10.1007/s00296-025-05858-8","DOIUrl":"10.1007/s00296-025-05858-8","url":null,"abstract":"<p><p>Reduced quality of life in patients with myositis is partly due to impairments in muscle strength, muscle endurance and functional capacity. In a recent randomised controlled trial (RCT) (NCT04486261) we showed that high-intensity resistance training improved quality of life, muscle strength, and endurance. This follow-up study aimed to investigate if these improvements remained persistent one year after completing 16 weeks of high-intensity resistance training. A total of 32 participants (intervention group (IG): 15; control group (CG): 17) were enrolled in the RCT, with 27 (IG: 13; CG: 14) completing the 1-year follow-up. Outcomes were assessed at three time points: baseline (weeks - 4 - 0), post-intervention (weeks 17-18), and 1-year follow-up (weeks 52-54). Outcomes included quality of life (QoL, SF36), functional capacity, muscle endurance (functional index 3 (FI3)), body composition (DEXA), and disease activity/damage, including manual muscle test 8 (MMT8). Training-induced improvements in muscle endurance (FI3) remained at 1-year follow-up, with a mean change of 10.7 (CI95: 2.2;19.1) in favour of IG (p = 0.01). Within-group improvements in IG were sustained for QoL (SF36, physical component summary) (4.8 (CI95: 0.9;8.7), p = 0.02), muscle strength (MMT8) (1.8 (CI95: 0.8; 2.9), p < 0.01), and functional capacity measures (p ≤ 0.04), although not significantly different from CG at 1-year follow-up. Disease activity and disease damage were similar between IG and CG at 1-year follow-up. Patients with myositis completing 16 weeks of high-intensity resistance training showed sustained improvements in muscle endurance at 1-year follow-up compared to controls. Indications of lasting enhancements in quality of life and strength were also present, with no increase in disease activity or damage. NCT04486261.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"104"},"PeriodicalIF":3.2,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depicting gouty arthritis at the Royal Court of Spain: the case of Pablo de Valladolid (1587-1648), the jester of King Philip IV.","authors":"Amelian Madalin Bobu, Andrei Ionut Cucu, Antonio Perciaccante, Victor Asensi, Irina Iuliana Costache Enache, Raffaella Bianuci","doi":"10.1007/s00296-025-05866-8","DOIUrl":"10.1007/s00296-025-05866-8","url":null,"abstract":"","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"103"},"PeriodicalIF":3.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis - a retrospective analysis from the RHADAR database.","authors":"Linus Maximilian Risser, Torsten Witte, Matthias Englbrecht, Patrick-Pascal Strunz, Matthias Froehlich, Marc Schmalzing, Michael Gernert, Peter Bartz-Bazzanella, Cay von der Decken, Kirsten Karberg, Georg Gauler, Susanna Späthling-Mestekemper, Christoph Kuhn, Wolfgang Vorbrüggen, Martin Welcker, Stefan Kleinert","doi":"10.1007/s00296-025-05859-7","DOIUrl":"10.1007/s00296-025-05859-7","url":null,"abstract":"<p><p>Numerous biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have been approved for treating rheumatoid arthritis (RA), including Janus kinase inhibitors (JAKi), rituximab, abatacept, interleukin-6 inhibitors (IL-6i) and tumor necrosis factor inhibitors (TNFi). Real-world data regarding treatment persistence and drug survival in the time period following the approval of JAKI are limited. To investigate the persistence and drug survival of different (b/tsDMARDs) in patients with RA based on real-world data from German outpatients. We performed a retrospective analysis of RA patients in the German RHADAR database who received a newly prescribed therapy with a b/tsDMARD between January 15, 2015 and October 17, 2023. To compare drug survival, we used Cox regression analyses adjusted for age, sex and disease duration. We included 4678 patients (79.9% female, mean age 58.7 years, mean disease duration 11.7 years). TNFi (47.8%) and JAKi (29.4%) were most frequently prescribed. The five-year drug survival rate was highest for JAKi (68.3%), followed by TNFi (58.6%), IL-6i (58.6%), abatacept (55.0%), and rituximab (53.3%). Compared to JAKi, Cox regression showed a higher discontinuation risk for rituximab (HR 1.36, p = 0.015), abatacept (HR 1.46, p < 0.001), IL-6i (HR 1.20, p = 0.026), and TNFi (HR 1.29, p < 0.001). Rituximab had the highest two-year survival (70.3%) but a sharp decline afterward, with 60% of discontinuations occurring between March 2020 and July 2022. In a real-world setting in German outpatients with RA, JAKi was associated with longer drug survival than bDMARDS. There were no significant differences in treatment persistence among different bDMARDs.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"100"},"PeriodicalIF":3.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients with vasculitis present a poor oral health: results of the online cross-sectional survey from Canada (VASC-TOOTH Survey).","authors":"Jaume Mestre-Torres, Medha Soowamber, Justine Lafleur-Careau, Arick Faibish, Shaminder Stavroullakis, Nazrana Haq, Christian Pagnoux","doi":"10.1007/s00296-025-05857-9","DOIUrl":"10.1007/s00296-025-05857-9","url":null,"abstract":"<p><p>To describe oral health complications and related quality of life in patients with vasculitis. Survey to assess clinical variables, pertinent to oral and dental health in patients with vasculitis and using the Oral Health Impact Profile 14 (OHIP14) questionnaire. 226 patients answered the survey. Globally, 179 (79.2%) patients reported good oral and dental health before the vasculitis diagnosis, while 92 (40.7%) patients reported a worsening since the diagnosis of vasculitis. Patients with a worsened oral health had a longer disease duration (10.0 (1.0) vs. 7.4 (0.7) years; p < 0.05), and had more relapses in the previous 2 years (34.8% vs. 16.4%; p < 0.005). The median OHIP14 score was 4 (IQR: 0-10); 97 (48.7%) patients scored > 4 points. Patients with Takayasu arteritis and Behçet disease showed worse OHIP14 scores, had a longer disease course but were younger than those with better scores or other vasculitis diagnoses. A high proportion of patients with vasculitis, especially those with Takayasu arteritis or Behçet disease, reported oral or dental complications, with subsequent impaired oral health-related quality of life.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"98"},"PeriodicalIF":3.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Kinesio taping without physical therapy for knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.","authors":"Abdullah Yousef Aldalati, Ayham Mohammad Hussein, Bara M Hammadeh, Bassel Alrabadi, Moath Albliwi, Mohammad Abuassi","doi":"10.1007/s00296-025-05853-z","DOIUrl":"10.1007/s00296-025-05853-z","url":null,"abstract":"<p><p>Knee osteoarthritis (KOA) is a common musculoskeletal disorder causing pain and stiffness. Kinesio tape (KT) is a flexible tape used for various musculoskeletal conditions, including KOA. This study systematically evaluates the effectiveness of KT without conventional physical therapy for KOA. A comprehensive search was conducted through PubMed, Scopus, Cochrane Library, Embase, and Web of Science from inception to March 2025 for randomized trials evaluating KT without physical therapy for KOA (Prospero: CRD42024615432). The risk of bias was assessed using the ROB-2 tool, and the data analysis was conducted using Review Manager V5.4. A total of 16 randomized trials were included. KT significantly reduced the post-treatment pain at rest (MD: -0.75, 95% CI: -1.15, -0.34) and during movement (MD: -0.92, 95% CI: -1.65, -0.20) compared to sham KT. However, KT did not demonstrate a significant effect on long-term pain reduction. Additionally, KT significantly improved the WOMAC total score (MD: -0.60, 95% CI: -1.19, -0.01) and increased knee flexion range of motion (FROM) (MD: 6.04, 95% CI: 3.13, 8.96). However, KT showed no significant effect on knee extension range of motion (MD: -0.23, 95% CI: -1.70, 1.25). No risk of publication bias observed. KT reduces pain, improves function, and enhances knee FROM in KOA patients even without physical therapy. However, its long-term effects remain uncertain. Future studies should evaluate the long-term application of KT and its integration with other KOA management strategies. Prospero ID CRD42024615432.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"99"},"PeriodicalIF":3.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographics and clinical manifestations in patients with Behçet's disease: a retrospective observational study from a non-endemic country.","authors":"Lucija Prtenjača, Miroslav Mayer, Boris Karanović, Krešimir Rukavina, Marija Bakula, Ivan Padjen, Marija Šćepović-Ljucović, Ljiljana Smiljanić Tomičević, Branimir Anić, Marko Barešić","doi":"10.1007/s00296-025-05855-x","DOIUrl":"10.1007/s00296-025-05855-x","url":null,"abstract":"<p><p>Behçet's disease (BD) is a systemic vasculitis of unknown origin affecting both arterial and venous vessels, resulting in diverse clinical features. Its manifestations vary due to ethnic, geographic, and individual differences. Although the highest prevalence of BD is reported along the ancient Silk Road route, nowadays, due to population migrations, the disease can be detected worldwide. Our study aimed to evaluate the demographic and clinical characteristics of patients with BD in a cohort from a non-endemic country and compare it with other cohorts from endemic and non-endemic countries worldwide. Our retrospective observational case-series study included the data from a single Rheumatology centre. We analyzed the data from 38 patients (17 men and 21 women) with a mean age at diagnosis of 29 years ± SD 8.87 and with a mean follow-up of 12.7 years. The most common manifestations were oral (97.4%) and genital ulcerations (73.7%), skin (57.9%) and ophthalmological changes (63.1%). Other clinical manifestations, musculoskeletal (42.1%), vascular (18.4%), neurological (15.8%) and gastrointestinal (15.8%) were less common. HLA-B51 frequency was 51.5%, without significant difference between females and males (10:7 cases). All patients were treated with local therapy, while systemic glucocorticoids were given in 84.2%, followed by colchicine in 44.7%. Immunosuppressive / immunomodulator therapy (most common azathioprine) was administered in 68.4% of patients. Due to disease severity, 13.2% of patients required biological TNF- inhibitor. Although BD is most prevalent in endemic countries, the disease can be diagnosed worldwide. Due to the disease's complex pathogenesis, its varied presenting manifestations, and the lack of pathognomonic signs and symptoms, diagnosis can be delayed in non-endemic countries, leading to the untimely initiation of targeted treatment.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"102"},"PeriodicalIF":3.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discounting seems the most toxic dimension of invalidation in fibromyalgia: a cross-sectional analysis.","authors":"Heidi Willemse, Johanna E Vriezekolk, Rinie Geenen","doi":"10.1007/s00296-025-05850-2","DOIUrl":"10.1007/s00296-025-05850-2","url":null,"abstract":"<p><p>Invalidation, both discounting (overt negative social responses) and lack of understanding (absence of positive social responses), is a common problem in fibromyalgia. The 'Fibromyalgia Imbalance of Threat and Soothing Systems' (FITSS) model indicates that different neuropsychological processes may underlie these two components of invalidation. Guided by this model, the aim of the current study was to clarify the differentiation between these two components of invalidation by examining their association with fibromyalgia severity, anxiety, and depression. This cross-sectional study included the Illness Invalidation Inventory (3*I), the Fibromyalgia Impact Questionnaire (FIQ), and the Hospital and Depression Scale (HADS). Demographics of the 280 respondents with fibromyalgia were: mean age 42.6 ± 11.8 yrs., 95% female, mean FIQ score 59.1 ± 15,5, possible or probable cases of anxiety and depression, 49% and 42%, respectively. Regression analyses revealed that discounting was associated with severity of fibromyalgia (t = 4.10, β = 0.34, p <.001), anxiety (t = 3.50, β = 0.29, p <.001) and depression (t = 3.64, β = 0.30, p <.001) symptoms. Neither lack of understanding (-1.62 ≤ t ≤.10, -0.13 ≤ β ≤ 0.01, p ≥ 0.11) nor the interaction of discounting and lack of understanding (-0.19 ≤ t ≤ 1.10, -0.01 ≤ β ≤ 0.07, p ≥ 0.27) was related to any of the outcome variables. The total model accounted for 8.8%, 5.3%, and 8.3% (adjusted R²) of variance in fibromyalgia severity, anxiety, and depression, respectively. In relation to both mental and physical health, discounting seems the most toxic dimension of invalidation in fibromyalgia. This suggests that overt negative responses should get attention in its management, especially in more severe fibromyalgia. Both people with fibromyalgia and people in their environment have a role in reducing invalidation.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"101"},"PeriodicalIF":3.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased fear of falling in primary Sjögren's syndrome: kinesiophobia, impaired balance and poor sleep quality as triggering factors.","authors":"Serife Seyda Zengin Acemoglu, Ayşegül Özdoğan Bircan, İpek Türk, Ilke Coskun Benlidayi, Sariyildiz Aylin, İlker Ünal","doi":"10.1007/s00296-025-05847-x","DOIUrl":"10.1007/s00296-025-05847-x","url":null,"abstract":"<p><p>The aim of this study was to explore the link between fear of falling and factors that may contribute to falls in patients with primary Sjögren's syndrome (pSS). Our study included a total of 67 patients with pSS, aged between 18 and 65. The following tests were performed on each of them by the same researcher: (I) Pain Quality Assessment Scale (PQAS); (II) Berg Balance Scale (BBS); (III) Pittsburgh Sleep Quality Index (PSQI); (IV) Medical Outcomes Study 36-Item Short Form Health Survey (SF-36); (V) Tampa Kinesiophobia Fatigue Scale Questionnaire (TSK-F); (VI) International Falls Efficiency Scale (FES-I); (VII) Timed Up And Go Test (TUG). Disease activities were recorded using the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) criteria. The following factors were associated with a fear of falling: (I) Deterioration in sleep quality (p = 0.031), (II) A decline in general health perception (p < 0.001), (III) Increased severity of pain (p < 0.001), (IV) Kinesiophobia (p < 0.001), (V) Difficulties with timely getting up and walking (p < 0.001), (VI) Increased disease activity (p < 0.001). There is no information available regarding the prevalence or contributing factors of fear of falling in individuals with pSS. This is the first study to examine fear of falling and contributing factors cross-sectionally in a sample of adults with pSS. These findings could aid in the development of a screening instrument to find modifiable risk factors for individuals with pSS who are susceptible to falling anxiety.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"97"},"PeriodicalIF":3.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}